Thursday , 18 July 2019
Breaking News

Tag Archives: pharmaceuticals

Torrent Pharmaceuticals soars on the bourses

Torrent Pharmaceuticals is currently trading at Rs. 1547.35, up by 34.80 points or 2.30% from its previous closing of Rs. 1511.45 on the BSE. The scrip opened at Rs. 1507.15 and has touched a high and low of Rs. 1552.45 and Rs. 1504.25 respectively. So far 5510 shares were traded on the counter. The BSE group ‘A’ stock of face ... Read More »

Glaxosmithkline Pharmaceuticals rises on the BSE

Mumbai : Glaxosmithkline Pharmaceuticals is currently trading at Rs. 1232.00, up by 2.15 points or 0.17% from its previous closing of Rs. 1229.85 on the BSE. The scrip opened at Rs. 1229.85 and has touched a high and low of Rs. 1238.90 and Rs. 1225.20 respectively. The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 ... Read More »

IOL Chemicals and Pharmaceuticals prepays terms loan of Rs 27.57 crore

IOL Chemicals and Pharmaceuticals has made the pre-payment of term loan of Rs 27.57 crore due to banks on May 29, 2019 in addition to regular repayment schedule. Thus, the company made the pre-payment of term loan of aggregate amount of Rs 47.62 crore till May 29, 2019, to reduce the debt of the company. IOL Chemicals and Pharmaceuticals is ... Read More »

Alembic Pharmaceuticals gets USFDA approval for Solifenacin Succinate Tablets

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Solifenacin Succinate Tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Vesicare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc. Solifenacin Succinate Tablet is a muscarinic antagonist indicated ... Read More »

Torrent Pharmaceuticals gains on raising Rs 100 crore via CPs

Torrent Pharmaceuticals is currently trading at Rs. 1666.70, up by 19.75 points or 1.20% from its previous closing of Rs. 1646.95 on the BSE. The scrip opened at Rs. 1681.60 and has touched a high and low of Rs. 1681.60 and Rs. 1649.05 respectively. So far 734 shares were traded on the counter. The BSE group ‘A’ stock of face ... Read More »

Glenmark Pharmaceuticals announces first in the world launch of its novel, globally-researched, latest-in-class diabetes medicine “Remogliflozin” in India

Udaipur : Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, today announced the launch of its novel,patent protected and globally-researched sodium glucose co-transporter (SGLT2)inhibitor Remogliflozinetabonate (Remogliflozin) in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults. SGLT2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by acting on the SGLT2 receptors ... Read More »

Glenmark Pharmaceuticals gains on the bourses

Glenmark Pharmaceuticals is currently trading at Rs. 595.85, up by 4.20 points or 0.71% from its previous closing of Rs. 591.65 on the BSE. The scrip opened at Rs. 581.10 and has touched a high and low of Rs. 602.45 and Rs. 581.10 respectively. So far 25594 shares were traded on the counter. The BSE group ‘A’ stock of face ... Read More »

Torrent Pharmaceuticals raises Rs 200 crore via CPs

Torrent Pharmaceuticals has raised funds through issuance of Commercial Paper (CPs) for an amount of approximately Rs 200 crore on May 03, 2019. The Tenure of the instrument is 136 days, having a maturity date of September 16, 2019. Credit rating agency, ICRA has granted rating of ‘A1 +’ for issuance of Commercial papers by the company. Torrent Pharmaceuticals is ... Read More »

Glenmark pharmaceuticals’ arm enters into co-promotion agreement with Otonomy

Glenmark pharmaceuticals’ subsidiary — Glenmark Therapeutics Inc., USA has entered into co-promotion agreement with Otonomy, Inc. a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris (olopatadine hydrochloride (665 mcg) and ... Read More »